In vivo efficacy in WT mice that bearing commercialized murine cancer cells are widely used for early prove of conception for anti-mouse antibody on indicated targets.
|Cancer Type||Name of Cell Line|
|Renal||E.G7-OVA, P388D1, EL4, YAC-1, L5178Y TK+/- clone|
|Myeloma||P3X63Ag8, SP2/0, FO|
(Table) Available murine cancer cells in LIDE. (Figure) MC38 murine colon cancer cells was inoculated into the right flank in C57BL/6J mice. Two anti-mPD-1 antibody, ab1 and ab2, were given at 5 mg/kg bi-weekly for 6 injections via i.v. or i.p., respectively, and demonstrated good anti-tumor effect.
In order to evaluate anti-human antibody, syngeneic model with both mice and murine cancer cells humanized should be constructed and applied accordingly.
(Left) Extracellular domain of both murine cancer cells (e.g.> PD-L1) and mice (e.g.> PD-1 on murine T cells) were replaced with humanized structure, while the promoter region asd well as intracellular signaling were maintained as previous. (Right) Flowchart of in vivo efficacy in humanized syngeneic models.
|Commercial available GEMM mice|
|More TG mice models, feel free to contact LIDE|
TAA1 overexpressed MC38 murine colon cancer cells (MC38-TAA1) was inoculated into the right flank in huPD-L1 transgenic mice. Both anti-huPD-L1 antibody (3 mg/kg, i.p., bi-weekly for 3 weeks) and anti-huPD-L1/TGFβ BsAb (3.6 mg/kg, i.p., bi-weekly for 3 weeks) demonstrated mediate anti-tumor effect.